Gary Gilliland, the former head of cancer research at Merck
and the Vice President for Precision Medicine at Penn Medicine, and Alan List,
the President and CEO of Moffit Cancer Center, for their thoughts on the data.
“It’s very interesting data but it’s very early, they have
small numbers of patients with modest follow up,” says Gilliland. “I hate the
hype that comes out around this because these patients are so desperate for
treatments.”
In the exciting column: Four of 18 patients had blood test
results consistent with a complete remission of disease, and one more with a
partial remission and three with clinical improvement. Read more.
No comments:
Post a Comment